Top of page| DOCTOR FUNGUS
CME program - "New Developments in the Treatment of Invasive Fungal Disease" Highlights from the 12th European Congress of Clinical Microbiology and Infectious Diseases |
||
|
PROGRAM DIRECTORS
|
||
|
John G. Bartlett, MD Professor Department of Medicine Chief Division of Infectious Diseases Johns Hopkins University School of Medicine Baltimore, Maryland • Dr Bartlett reports serving on the HIV advisory board for Abbott Laboratories and Merck & Co, Inc. John H. Rex, MD, FACP Professor Department of Medicine Section of Infectious Diseases University of Texas Medical School Houston, Texas • Dr Rex reports receiving grants and/or research support from, serving as a consultant to, or receiving honoraria from Bristol-Myers Squibb Company; Fujisawa Pharmaceutical Co, Ltd; Gilead Sciences, Inc; Janssen Pharmaceutica; Merck & Co, Inc; Ortho Biotech Products, LP; Pfizer Inc; Schering-Plough Corporation; Lipsome Company, Inc; and Versicor Inc. |
||
|
PARTICIPATING FACULTY |
||
|
Manuel Cuenca-Estrella, MD, PhD Clinical Researcher Unidad de Micologia Instituto de Salud Carlos III Centro Nacional de Microbiologia Madrid, Spain • Dr Cuenca-Estrella reports no financial or advisory relationships with pharmaceutical companies related to this activity. Renée Grillot, PhD Professor Parasitologie-Mycologie Médicale Centre Hospitalier Universitaire et Université Joseph Fourier Grenoble, France • Prof Grillot reports no financial or advisory relationships with pharmaceutical companies related to this activity. Bart-Jan Kullberg, MD Associate Professor of Medicine Department of Internal Medicine University Hospital Nijmegen Nijmegen, The Netherlands • Dr Kullberg reports receiving grants and/or research support from Pfizer Inc, and receiving honoraria from Pfizer Inc; Schering-Plough Corporation; and Ortho Biotech Products, LP. Ruth Matthews, MD, PhD, FRCPath Research and Development Director NeuTec Pharma plc Manchester Royal Infirmary Manchester, United Kingdom • Prof Matthews is the Founding Director/Research and Development Director of NeuTec Pharma plc. John R. Perfect, MD Professor of Medicine Associate Professor of Microbiology Director, Mycology Research Unit Duke University Medical Center Durham, North Carolina • Dr Perfect reports receiving grants and/or research support from Elan Corporation; Fujisawa Pharmaceutical Co, Ltd; Merck & Co, Inc; Pfizer Inc; Pliva dd; and Schering-Plough Corporation.
Advanced Studies in Medicine provides disclosure information from contributing authors, lead presenters, and participating faculty. Advanced Studies in Medicine does not provide disclosure information from authors of abstracts and poster presentations. The reader shall be advised that these contributors may or may not maintain financial relationships with pharmaceutical companies.
Off Label Product Discussion Faculty have disclosed that their articles have referenced the following off-label/unapproved uses of drugs or products: Product Posaconazole — Dr Kullberg Mycograb® — Prof Matthews | ||
| Close this window | ||